PlainRecalls
FDA Drug Moderate Class II Terminated

Glycopyrrolate Injection, USP, 0.4 mg/2 mL (0.2 mg/mL) 2 mL Single Dose Vial X 25 vials carton, Rx Only, Manufactured for: Accord Healthcare, Inc. Durham, NC 27703, USA. Manufactured by: Intas Pharmaceuticals Limited, Pharmez, Ahmedabad-382 213, INDIA 2 ML vial NDC 16729-472-30 UPC 3 16729 47230 2; carton NDC 16729-472-08 UPC 3 16729 47208 1

Reported: March 8, 2023 Initiated: February 7, 2023 #D-0397-2023

Product Description

Glycopyrrolate Injection, USP, 0.4 mg/2 mL (0.2 mg/mL) 2 mL Single Dose Vial X 25 vials carton, Rx Only, Manufactured for: Accord Healthcare, Inc. Durham, NC 27703, USA. Manufactured by: Intas Pharmaceuticals Limited, Pharmez, Ahmedabad-382 213, INDIA 2 ML vial NDC 16729-472-30 UPC 3 16729 47230 2; carton NDC 16729-472-08 UPC 3 16729 47208 1

Reason for Recall

CGMP Deviations: recalling drug products following an FDA inspection.

Details

Recalling Firm
Accord Healthcare, Inc.
Units Affected
5,273 vials
Distribution
United States including Puerto Rico and Canada
Location
Durham, NC

Frequently Asked Questions

What product was recalled?
Glycopyrrolate Injection, USP, 0.4 mg/2 mL (0.2 mg/mL) 2 mL Single Dose Vial X 25 vials carton, Rx Only, Manufactured for: Accord Healthcare, Inc. Durham, NC 27703, USA. Manufactured by: Intas Pharmaceuticals Limited, Pharmez, Ahmedabad-382 213, INDIA 2 ML vial NDC 16729-472-30 UPC 3 16729 47230 2; carton NDC 16729-472-08 UPC 3 16729 47208 1. Recalled by Accord Healthcare, Inc.. Units affected: 5,273 vials.
Why was this product recalled?
CGMP Deviations: recalling drug products following an FDA inspection.
Which agency issued this recall?
This recall was issued by the FDA Drug on March 8, 2023. Severity: Moderate. Recall number: D-0397-2023.